Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165815455> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2165815455 endingPage "1705" @default.
- W2165815455 startingPage "1703" @default.
- W2165815455 abstract "This editorial refers to ‘Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial’[†][1], by K.K.Teo et al. , on page 1743 and ‘Renin–angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure’[‡][2], by E. Sorbets et al. , on page 1760. A series of randomized clinical trials demonstrated that when compared with placebo, angiotensin-converting enzyme (ACE) inhibitiors or angiotensin receptor blockers (ARBs) were drugs able to improve the prognosis of patients with heart failure accompanied by low ejection fraction, patients with a myocardial infarction (MI), and patients with chronic kidney disease (CKD; most notably demonstrated by ARBs in diabetic nephropathy), allowing the recognition by Guidelines that blockade of the renin–angiotensin system (RAS) must be used in all these situations. The use of ACE inhibitors and also of ARBs was later expanded to patients with an increased global cardiovascular (CV) risk, patients with stable coronary artery disease (CAD), diabetic patients independently of the presence of established CV or renal disease, and hypertensive patients if clustering of CV risk factors or target organ damage was present. Table 1 lists the different clinical situations where RAS blockade is indicated according to Guidelines that led to the wide use of ACE inhibitors and ARBs in clinical practice; as an example, either alone or in combination, these drugs are prescribed in > 30–40% of the hypertensive population.1 View this table:Table 1 Clinical situations where the use of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker has demonstrated positive effectsRecently, the first orally active renin inhibitor was launched as an antihypertensive drug able theoretically to improve the degree … [1]: #fn-2 [2]: #fn-3" @default.
- W2165815455 created "2016-06-24" @default.
- W2165815455 creator A5019931026 @default.
- W2165815455 date "2014-04-09" @default.
- W2165815455 modified "2023-10-01" @default.
- W2165815455 title "Renin-angiotensin system blockade: time for a reappraisal?" @default.
- W2165815455 cites W1521640407 @default.
- W2165815455 cites W1969319209 @default.
- W2165815455 cites W1990833193 @default.
- W2165815455 cites W1993382349 @default.
- W2165815455 cites W2001791400 @default.
- W2165815455 cites W2015886692 @default.
- W2165815455 cites W2044049836 @default.
- W2165815455 cites W2085879694 @default.
- W2165815455 cites W2093276210 @default.
- W2165815455 cites W2098418963 @default.
- W2165815455 cites W2121267642 @default.
- W2165815455 cites W2137266255 @default.
- W2165815455 cites W2138862624 @default.
- W2165815455 cites W2143360708 @default.
- W2165815455 cites W2146058909 @default.
- W2165815455 cites W2162068624 @default.
- W2165815455 cites W2168507847 @default.
- W2165815455 cites W4248446744 @default.
- W2165815455 doi "https://doi.org/10.1093/eurheartj/ehu129" @default.
- W2165815455 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5994824" @default.
- W2165815455 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25152949" @default.
- W2165815455 hasPublicationYear "2014" @default.
- W2165815455 type Work @default.
- W2165815455 sameAs 2165815455 @default.
- W2165815455 citedByCount "2" @default.
- W2165815455 countsByYear W21658154552015 @default.
- W2165815455 countsByYear W21658154552016 @default.
- W2165815455 crossrefType "journal-article" @default.
- W2165815455 hasAuthorship W2165815455A5019931026 @default.
- W2165815455 hasBestOaLocation W21658154551 @default.
- W2165815455 hasConcept C126322002 @default.
- W2165815455 hasConcept C170493617 @default.
- W2165815455 hasConcept C198710026 @default.
- W2165815455 hasConcept C2778468042 @default.
- W2165815455 hasConcept C71924100 @default.
- W2165815455 hasConcept C84393581 @default.
- W2165815455 hasConceptScore W2165815455C126322002 @default.
- W2165815455 hasConceptScore W2165815455C170493617 @default.
- W2165815455 hasConceptScore W2165815455C198710026 @default.
- W2165815455 hasConceptScore W2165815455C2778468042 @default.
- W2165815455 hasConceptScore W2165815455C71924100 @default.
- W2165815455 hasConceptScore W2165815455C84393581 @default.
- W2165815455 hasFunder F4320332161 @default.
- W2165815455 hasIssue "26" @default.
- W2165815455 hasLocation W21658154551 @default.
- W2165815455 hasLocation W21658154552 @default.
- W2165815455 hasLocation W21658154553 @default.
- W2165815455 hasLocation W21658154554 @default.
- W2165815455 hasOpenAccess W2165815455 @default.
- W2165815455 hasPrimaryLocation W21658154551 @default.
- W2165815455 hasRelatedWork W2044747643 @default.
- W2165815455 hasRelatedWork W2047608102 @default.
- W2165815455 hasRelatedWork W2051519978 @default.
- W2165815455 hasRelatedWork W2068374317 @default.
- W2165815455 hasRelatedWork W2077998387 @default.
- W2165815455 hasRelatedWork W2092637011 @default.
- W2165815455 hasRelatedWork W2126797993 @default.
- W2165815455 hasRelatedWork W2149410839 @default.
- W2165815455 hasRelatedWork W2322088208 @default.
- W2165815455 hasRelatedWork W2418574610 @default.
- W2165815455 hasVolume "35" @default.
- W2165815455 isParatext "false" @default.
- W2165815455 isRetracted "false" @default.
- W2165815455 magId "2165815455" @default.
- W2165815455 workType "article" @default.